Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 121 to 124 of 124 entries
Sorted by: Best Match Show Resources per page
Bempedoic acid as a PPARα activator: new perspectives for hepatic steatosis treatment in a female rat experimental model.

Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis

Bentanachs R, Velázquez AM, Sánchez RM, Alegret M, Laguna JC, Roglans N.
PMID: 34887111
Clin Investig Arterioscler. 2021 Dec 06; doi: 10.1016/j.arteri.2021.09.004. Epub 2021 Dec 06.

INTRODUCTION: In its initial stages, nonalcoholic fatty liver disease presents hypertriglyceridemia and accumulation of lipids in the liver (hepatic steatosis). Bempedoic acid is an ATP:citrate lyase inhibitor that promotes a dual inhibition of the synthesis of cholesterol and fatty...

Cite
Bentanachs R, Velázquez AM, Sánchez RM, et al. El ácido bempedoico como activador PPAR?: Nuevas perspectivas para el tratamiento de la esteatosis hepática en un modelo experimental de rata hembra. Bempedoic acid as a PPARα activator: new perspectives for hepatic steatosis treatment in a female rat experimental model. Clin Investig Arterioscler. 2021;doi: 10.1016/j.arteri.2021.09.004.
Bentanachs, R., Velázquez, A. M., Sánchez, R. M., Alegret, M., Laguna, J. C., & Roglans, N. (2021). El ácido bempedoico como activador PPAR?: Nuevas perspectivas para el tratamiento de la esteatosis hepática en un modelo experimental de rata hembra. Bempedoic acid as a PPARα activator: new perspectives for hepatic steatosis treatment in a female rat experimental model. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, . https://doi.org/10.1016/j.arteri.2021.09.004
Bentanachs, Roger, et al. "El ácido bempedoico como activador PPAR?: Nuevas perspectivas para el tratamiento de la esteatosis hepática en un modelo experimental de rata hembra." Bempedoic acid as a PPARα activator: new perspectives for hepatic steatosis treatment in a female rat experimental model. Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis vol. (2021). doi: https://doi.org/10.1016/j.arteri.2021.09.004
Bentanachs R, Velázquez AM, Sánchez RM, Alegret M, Laguna JC, Roglans N. El ácido bempedoico como activador PPAR?: Nuevas perspectivas para el tratamiento de la esteatosis hepática en un modelo experimental de rata hembra. Bempedoic acid as a PPARα activator: new perspectives for hepatic steatosis treatment in a female rat experimental model. Clin Investig Arterioscler. 2021 Dec 06; doi: 10.1016/j.arteri.2021.09.004. Epub 2021 Dec 06. Spanish. PMID: 34887111.
Copy Download .nbib Format: NLM
Evidence of a Down Syndrome Keratopathy: A Three-Dimensional (3-D) Morphogeometric and Volumetric Analysis.

Journal of personalized medicine

Toprak I, Cavas F, Vega A, Velázquez JS, Alio Del Barrio JL, Alio JL.
PMID: 33573177
J Pers Med. 2021 Jan 30;11(2). doi: 10.3390/jpm11020082.

The aim of this study was to investigate whether a different and abnormal corneal profile is present in Down syndrome (DS) by personalized three-dimensional (3D) modelling. This single-centre cross-sectional study included 43 patients with DS (43 eyes) and 58...

Cite
Toprak I, Cavas F, Vega A, et al. Evidence of a Down Syndrome Keratopathy: A Three-Dimensional (3-D) Morphogeometric and Volumetric Analysis. J Pers Med. 2021;11(2)doi: 10.3390/jpm11020082.
Toprak, I., Cavas, F., Vega, A., Velázquez, J. S., Alio Del Barrio, J. L., & Alio, J. L. (2021). Evidence of a Down Syndrome Keratopathy: A Three-Dimensional (3-D) Morphogeometric and Volumetric Analysis. Journal of personalized medicine, 11(2), . https://doi.org/10.3390/jpm11020082
Toprak, Ibrahim, et al. "Evidence of a Down Syndrome Keratopathy: A Three-Dimensional (3-D) Morphogeometric and Volumetric Analysis." Journal of personalized medicine vol. 11,2 (2021). doi: https://doi.org/10.3390/jpm11020082
Toprak I, Cavas F, Vega A, Velázquez JS, Alio Del Barrio JL, Alio JL. Evidence of a Down Syndrome Keratopathy: A Three-Dimensional (3-D) Morphogeometric and Volumetric Analysis. J Pers Med. 2021 Jan 30;11(2). doi: 10.3390/jpm11020082. PMID: 33573177; PMCID: PMC7911434.
Copy Download .nbib Format: NLM
Dual transcriptomic analysis reveals metabolic changes associated with differential persistence of human pathogenic bacteria in leaves of Arabidopsis and lettuce.

G3 (Bethesda, Md.)

Jacob C, Velásquez AC, Josh NA, Settles M, He SY, Melotto M.
PMID: 34550367
G3 (Bethesda). 2021 Dec 08;11(12). doi: 10.1093/g3journal/jkab331.

Understanding the molecular determinants underlying the interaction between the leaf and human pathogenic bacteria is key to provide the foundation to develop science-based strategies to prevent or decrease the pathogen contamination of leafy greens. In this study, we conducted...

Cite
Jacob C, Velásquez AC, Josh NA, et al. Dual transcriptomic analysis reveals metabolic changes associated with differential persistence of human pathogenic bacteria in leaves of Arabidopsis and lettuce. G3 (Bethesda). 2021;11(12)doi: 10.1093/g3journal/jkab331.
Jacob, C., Velásquez, A. C., Josh, N. A., Settles, M., He, S. Y., & Melotto, M. (2021). Dual transcriptomic analysis reveals metabolic changes associated with differential persistence of human pathogenic bacteria in leaves of Arabidopsis and lettuce. G3 (Bethesda, Md.), 11(12), . https://doi.org/10.1093/g3journal/jkab331
Jacob, Cristián, et al. "Dual transcriptomic analysis reveals metabolic changes associated with differential persistence of human pathogenic bacteria in leaves of Arabidopsis and lettuce." G3 (Bethesda, Md.) vol. 11,12 (2021). doi: https://doi.org/10.1093/g3journal/jkab331
Jacob C, Velásquez AC, Josh NA, Settles M, He SY, Melotto M. Dual transcriptomic analysis reveals metabolic changes associated with differential persistence of human pathogenic bacteria in leaves of Arabidopsis and lettuce. G3 (Bethesda). 2021 Dec 08;11(12). doi: 10.1093/g3journal/jkab331. PMID: 34550367; PMCID: PMC8664426.
Copy Download .nbib Format: NLM
Electrocerebral Signature of Cardiac Death.

Neurocritical care

Matory AL, Alkhachroum A, Chiu WT, Eliseyev A, Doyle K, Rohaut B, Egbebike JA, Velazquez AG, Der-Nigoghossian C, Paniker L, Prager KM, Agarwal S, Roh D, Park S, Claassen J.
PMID: 34184175
Neurocrit Care. 2021 Dec;35(3):853-861. doi: 10.1007/s12028-021-01233-0. Epub 2021 Jun 28.

BACKGROUND: Electroencephalography (EEG) findings following cardiovascular collapse in death are uncertain. We aimed to characterize EEG changes immediately preceding and following cardiac death.METHODS: We retrospectively analyzed EEGs of patients who died from cardiac arrest while undergoing standard EEG monitoring...

Cite
Matory AL, Alkhachroum A, Chiu WT, et al. Electrocerebral Signature of Cardiac Death. Neurocrit Care. 2021;35(3):853-861doi: 10.1007/s12028-021-01233-0.
Matory, A. L., Alkhachroum, A., Chiu, W. T., Eliseyev, A., Doyle, K., Rohaut, B., Egbebike, J. A., Velazquez, A. G., Der-Nigoghossian, C., Paniker, L., Prager, K. M., Agarwal, S., Roh, D., Park, S., & Claassen, J. (2021). Electrocerebral Signature of Cardiac Death. Neurocritical care, 35(3), 853-861. https://doi.org/10.1007/s12028-021-01233-0
Matory, Adu L, et al. "Electrocerebral Signature of Cardiac Death." Neurocritical care vol. 35,3 (2021): 853-861. doi: https://doi.org/10.1007/s12028-021-01233-0
Matory AL, Alkhachroum A, Chiu WT, Eliseyev A, Doyle K, Rohaut B, Egbebike JA, Velazquez AG, Der-Nigoghossian C, Paniker L, Prager KM, Agarwal S, Roh D, Park S, Claassen J. Electrocerebral Signature of Cardiac Death. Neurocrit Care. 2021 Dec;35(3):853-861. doi: 10.1007/s12028-021-01233-0. Epub 2021 Jun 28. PMID: 34184175.
Copy Download .nbib Format: NLM
Showing 121 to 124 of 124 entries